Combination treatment may improve survival of breast cancer patients with brain metastases
Thursday, November 1, 2012 - 16:00
in Health & Medicine
Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. Investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.